Table of Contents
What changed
Revenue was essentially flat at NZ$116.9m versus NZ$117.0m (-0.1%), but everything below the top line deteriorated sharply. Operating profit fell 77.8% to NZ$3.0m, PBT fell 94.8% to NZ$0.6m, and NPAT fell 94.5% to NZ$0.4m. The damage sits in the New Zealand segment: NZ revenue slipped to NZ$87.9m from NZ$89.2m, but segment result collapsed to NZ$4.1m from NZ$12.8m, implying EBIT margin fell from 14.4% to 4.7%. Australia grew revenue modestly to NZ$29.0m but swung from a NZ$0.4m profit to a NZ$0.7m loss.
Operating cash flow halved to NZ$9.9m from NZ$19.6m, and capex stepped up to NZ$7.3m from NZ$1.9m (6.2% of revenue versus 1.6%), leaving pre-lease free cash flow of NZ$2.6m against NZ$17.7m prior. Cash on hand still rose to NZ$13.7m from NZ$8.6m, gross borrowings edged up to NZ$61.5m, and net debt eased to NZ$47.8m from NZ$51.0m. No interim dividend was declared despite the FY21 stated intention to resume payments alongside this result.
What matters
- NZ margin is the story, not revenue. With group sales flat, the ~970bps compression in NZ segment margin did almost all of the earnings damage. Management attributed this to one-off Covid-19 restrictions and ongoing global shipping disruption, but neither effect is quantified in a reconciliation.
- Capital allocation inflected. Capex more than tripled in absolute terms while earnings collapsed, and the board did not consider an interim dividend despite the FY21 flagged intent to resume. ROE dropped to 0.5% from 9.1%.
- Balance sheet direction is still the bright spot. Net debt fell roughly NZ$3.2m year on year and cash is up NZ$5.1m, so leverage is strengthening even as profitability is weakening — the deleveraging thesis is intact but is now being financed by working capital (trade debtor days fell from 53.8 to 43.7) rather than earnings.
Expectations
Management stated the result was consistent with guidance issued in September 2021, so there is no upside surprise signal here. Prior shape context is distorted: HY21 represented 88.5% of FY21 NPAT, meaning the implied FY21 second half was only NZ$1.0m, so there is no clean run-rate to annualise against. Annualised HY22 revenue of NZ$233.7m sits fractionally above FY21's NZ$232.3m, supporting a flat top-line run-rate but saying nothing about whether NZ margin rebuilds. No quantified forward-work, order-book or FY22 earnings target was disclosed.
Quality of result
The earnings fall is operational, not cosmetic. Tax distortion is minor (ETR 25.2% vs 29.2%) and the PBT and NPAT declines are within 0.3pp of each other, so PBT and NPAT tell the same story. There are no discontinued-operation or disposal losses to blame — the collapse sits in operating profit, primarily NZ.
Cash quality is more nuanced. Operating cash flow still covered the collapsed NPAT many times over (FCF pre-lease to NPAT at 627%), but in absolute terms OCF halved and the NZ$10.1-day reduction in receivable days contributed to what cash did come in. Inventory days rose 3.5 days, partially offsetting. With capex stepping up sharply, pre-lease FCF of NZ$2.6m is modest, and the net debt improvement was only NZ$3.2m year on year — so the deleveraging pace also slowed. Durable components are few; most of the improvement versus a hypothetical worse outcome is balance-sheet assisted.
Unresolved
- How much of the NZ margin compression is genuinely one-off Covid/shipping versus structural cost inflation that persists into HY23? No quantified bridge was provided.
- Why was the Australia segment loss-making despite revenue growth, and is it a pricing, mix, or cost issue?
- What does the absence of an interim dividend signal about the board's confidence in second-half cash generation, given FY21 had explicitly flagged resumption with these results?
- Why has capex stepped up so materially (NZ$7.3m vs NZ$1.9m), and is this a one-half catch-up or a sustained higher run-rate?
- No EBITDA, net-debt-to-EBITDA, or adjusted earnings reconciliation was disclosed, so covenant headroom cannot be assessed from the extract.
This briefing cannot assess valuation, covenant position, or the split between one-off Covid/shipping drag and structural margin erosion, because none of those items were quantified in the supplied materials.
Key metrics
| Metric | HY22 | HY21 | Change |
|---|---|---|---|
| Revenue | $116.9m | $117.0m | -0.1% ↓ |
| Net profit after tax | $0.4m | $7.6m | -94.5% ↓ |
| Net cash inflow from operating activities | $9.9m | $19.6m | -49.4% ↓ |
| Operating profit | $3.0m | $13.7m | -77.8% ↓ |
| Profit before tax | $0.6m | $10.7m | -94.8% ↓ |
| Cash and cash equivalents | $13.7m | $8.6m | +58.6% ↑ |
| Total assets | $241.2m | $242.7m | -0.6% ↓ |
Reference: annolyse.ai/briefings/mpg-hy22
Segment breakdown
| Segment | Current revenue | Prior revenue | Current result | Mix shift |
|---|---|---|---|---|
| New Zealand | $87.9m | $89.2m | $4.1m | -1.1pp |
| Australia | $29m | $27.8m | −$0.7m | +1.1pp |
Reference: annolyse.ai/briefings/mpg-hy22
Analytical metrics
| Metric | HY22 | HY21 | Context |
|---|---|---|---|
| PBT growth | -94.8% | — | — |
| Effective tax rate | 25.2% | 29.2% | — |
| FCF pre-lease | $2.6m | $17.7m | −$15.0m |
| FCF / NPAT | 627.2% | 233.5% | complementary conversion metric |
| Capex % revenue | 6.2% | 1.6% | — |
| Capex | −$7.3m | $1.9m | −$9.2m |
| Debtor days | 43.7 | 53.8 | -10.1 days |
| Inventory days | 34.1 | 30.6 | +3.5 days |
| Trade debtors | $28.0m | $34.5m | −$6.5m |
| Net debt | $47.8m | $51.0m | −$3.2m |
| Gross borrowings | $61.5m | $59.7m | +$1.8m |
| ROE (annualised) | 0.5% | 9.1% | Weakening |
| HY21 share of FY21 revenue | 50.4% | — | Other half was 49.6% |
| HY21 share of FY21 NPAT | 88.5% | — | Other half was 11.5% |
| Profit from continuing operations | $0.4m | — | — |
Reference: annolyse.ai/briefings/mpg-hy22
This analysis was generated using Annolyse, an AI-powered tool that extracts and analyses NZX company announcements. The underlying data is extracted from official company filings and verified against source documents. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.